Distinguished in Juvenile Primary Osteoporosis

Dr. Robin K. Dore

Rheumatology
12791 Newport Ave, Suite 201, 
Tustin, CA 
Offers Telehealth
Distinguished in Juvenile Primary Osteoporosis
12791 Newport Ave, Suite 201, 
Tustin, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robin Dore is a Rheumatologist in Tustin, California. Dr. Dore is rated as a Distinguished provider by MediFind in the treatment of Juvenile Primary Osteoporosis. Her top areas of expertise are Postmenopausal Osteoporosis, Rheumatoid Arthritis (RA), Osteoporosis, and Juvenile Primary Osteoporosis.

Her clinical research consists of co-authoring 13 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in CA
Hospital Affiliations
Providence St. Joseph Hospital
Uci Health-Orange
Memorialcare Saddleback Medical Center
Providence Mission Hospital
Hoag Memorial Hospital Presbyterian
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

12791 Newport Ave, Suite 201, Tustin, CA 92780

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 3 Less Clinical Trials

13 Total Publications

Associations of Cost Sharing With Rheumatoid Arthritis Disease Burden.
Associations of Cost Sharing With Rheumatoid Arthritis Disease Burden.
Journal: ACR open rheumatology
Published: December 11, 2022
Similar Doctors
Distinguished in Juvenile Primary Osteoporosis
Dr. Shirley W. Pang
Rheumatology
Distinguished in Juvenile Primary Osteoporosis
Dr. Shirley W. Pang
Rheumatology
2141 North Harbor Boulevard, Suite 25000, 
Fullerton, CA 
 (12.1 miles away)
714-626-8650
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shirley Pang is a Rheumatologist in Fullerton, California. Dr. Pang is rated as an Advanced provider by MediFind in the treatment of Juvenile Primary Osteoporosis. Her top areas of expertise are Juvenile Primary Osteoporosis, Postmenopausal Osteoporosis, Osteoporosis, and Rheumatoid Arthritis (RA). Dr. Pang is currently accepting new patients.

Distinguished in Juvenile Primary Osteoporosis
Dr. Elayne K. Garber
Rheumatology
Distinguished in Juvenile Primary Osteoporosis
Dr. Elayne K. Garber
Rheumatology

Elayne K Garber MD A Medical Corporation

8631 W 3rd St, Suite 700e, 
Los Angeles, CA 
 (39.6 miles away)
310-854-3539
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elayne Garber is a Rheumatologist in Los Angeles, California. Dr. Garber is rated as a Distinguished provider by MediFind in the treatment of Juvenile Primary Osteoporosis. Her top areas of expertise are Rheumatoid Arthritis (RA), Juvenile Primary Osteoporosis, Postmenopausal Osteoporosis, and Osteoporosis.

Distinguished in Juvenile Primary Osteoporosis
Dr. Glenn R. Ehresmann
Rheumatology
Distinguished in Juvenile Primary Osteoporosis
Dr. Glenn R. Ehresmann
Rheumatology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (31.2 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Glenn Ehresmann is a Rheumatologist in Los Angeles, California. Dr. Ehresmann is rated as a Distinguished provider by MediFind in the treatment of Juvenile Primary Osteoporosis. His top areas of expertise are Adult Still's Disease, Polymyositis, Rheumatoid Arthritis (RA), and Palindromic Rheumatism.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dore's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile